Skip to main
QDEL
QDEL logo

QuidelOrtho Corp (QDEL) Stock Forecast & Price Target

QuidelOrtho Corp (QDEL) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

QuidelOrtho Corp has demonstrated strong free cash flow generation, primarily driven by its leadership in point-of-care COVID and flu testing, which positions the company well for future prospects. The merger with Ortho has expanded its product portfolio, allowing QuidelOrtho to effectively compete with larger enterprises in the diagnostics market. Additionally, the transition of legacy operations to the Ortho IT platform is expected to yield long-term cost savings and operational efficiencies, supporting continued margin expansion.

Bears say

QuidelOrtho Corp faces significant challenges that contribute to a negative outlook, particularly due to uncertainty surrounding the launch of its Savanna product and potential loss of market share in the point-of-care and laboratory sectors. The company also risks margin contraction and may struggle with debt repayment, factors that could justify a revised sales multiple at 1.3x, the historical low for comparable non-molecular diagnostics companies. Additionally, ongoing issues related to endemic COVID impacts, ERP consolidation, and lack of clear guidance further compound the risk of achieving long-term financial targets, highlighting potential integration difficulties.

QuidelOrtho Corp (QDEL) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of QuidelOrtho Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About QuidelOrtho Corp (QDEL) Forecast

Analysts have given QuidelOrtho Corp (QDEL) a Buy based on their latest research and market trends.

According to 12 analysts, QuidelOrtho Corp (QDEL) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

QuidelOrtho Corp (QDEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.